Baker Ellis Asset Management’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.93M Hold
14,988
0.2% 88
2026
Q1
$1.8M Hold
14,988
0.21% 86
2025
Q4
$1.58M Sell
14,988
-749
-5% -$70.3K 0.19% 87
2025
Q3
$1.32M Buy
15,737
+2,649
+20% +$218K 0.16% 100
2025
Q2
$1.04M Sell
13,088
-180
-1% -$14.3K 0.14% 102
2025
Q1
$1.19M Buy
13,268
+340
+3% +$31.7K 0.17% 96
2024
Q4
$1.29M Buy
12,928
+840
+7% +$86.6K 0.19% 87
2024
Q3
$1.37M Buy
12,088
+683
+6% +$81.1K 0.19% 90
2024
Q2
$1.41M Buy
11,405
+400
+4% +$51.5K 0.21% 85
2024
Q1
$1.45M Buy
11,005
+1,140
+12% +$141K 0.22% 88
2023
Q4
$1.08M Sell
9,865
-500
-5% -$51.9K 0.17% 104
2023
Q3
$1.07M Sell
10,365
-300
-3% -$32.3K 0.19% 96
2023
Q2
$1.23M Hold
10,665
0.21% 90
2023
Q1
$1.13M Hold
10,665
0.2% 93
2022
Q4
$1.18M Hold
10,665
0.23% 84
2022
Q3
$918K Buy
10,665
+415
+4% +$37K 0.2% 91
2022
Q2
$934K Hold
10,250
0.19% 96
2022
Q1
$841K Hold
10,250
0.15% 104
2021
Q4
$786K Sell
10,250
-600
-6% -$47.8K 0.14% 108
2021
Q3
$864K Hold
10,850
0.17% 105
2021
Q2
$844K Sell
10,850
-521
-5% -$38.8K 0.17% 100
2021
Q1
$836K Buy
11,371
+105
+0.9% +$7.75K 0.18% 98
2020
Q4
$879K Buy
11,266
+84
+0.8% +$6.42K 0.21% 91
2020
Q3
$885K Buy
11,182
+209
+2% +$16.4K 0.25% 85
2020
Q2
$810K Hold
10,973
0.24% 94
2020
Q1
$806K Buy
10,973
+4,266
+64% +$335K 0.29% 76
2019
Q4
$582K Sell
6,707
-14,693
-69% -$1.21M 0.16% 102
2019
Q3
$1.72M Hold
21,400
0.46% 63
2019
Q2
$1.71M Hold
21,400
0.45% 62
2019
Q1
$1.7M Sell
21,400
-2,009
-9% -$150K 0.47% 63
2018
Q4
$1.71M Sell
23,409
-315
-1% -$22.2K 0.52% 52
2018
Q3
$1.61M Sell
23,724
-5,908
-20% -$376K 0.41% 72
2018
Q2
$1.72M Sell
29,632
-413
-1% -$23.3K 0.45% 70
2018
Q1
$1.56M Hold
30,045
0.41% 71
2017
Q4
$1.61M Sell
30,045
-868
-3% -$48.1K 0.41% 73
2017
Q3
$1.89M Sell
30,913
-468
-1% -$28.4K 0.5% 61
2017
Q2
$1.92M Hold
31,381
0.53% 53
2017
Q1
$1.9M Sell
31,381
-165
-0.5% -$10K 0.54% 50
2016
Q4
$1.77M Sell
31,546
-45
-0.1% -$2.63K 0.52% 52
2016
Q3
$1.88M Buy
31,591
+367
+1% +$21.5K 0.57% 52
2016
Q2
$1.72M Buy
31,224
+314
+1% +$16.7K 0.54% 54
2016
Q1
$1.56M Buy
30,910
+680
+2% +$33.3K 0.52% 56
2015
Q4
$1.52M Hold
30,230
0.52% 54
2015
Q3
$1.43M Sell
30,230
-314
-1% -$16.7K 0.51% 59
2015
Q2
$1.66M Sell
30,544
-105
-0.3% -$5.89K 0.56% 50
2015
Q1
$1.68M Hold
30,649
0.53% 49
2014
Q4
$1.66M Sell
30,649
-2,777
-8% -$155K 0.56% 49
2014
Q3
$1.89M Sell
33,426
-996
-3% -$55.9K 0.65% 39
2014
Q2
$1.9M Sell
34,422
-1,949
-5% -$106K 0.65% 41
2014
Q1
$1.97M Sell
36,371
-105
-0.3% -$5.44K 0.68% 37
2013
Q4
$1.74M Sell
36,476
-157
-0.4% -$7.18K 0.61% 45
2013
Q3
$1.66M Buy
36,633
+210
+0.6% +$9.59K 0.63% 43
2013
Q2
$1.61M Buy
+36,423
New +$1.63M 0.64% 41

Other funds holding MRK

Baker Ellis Asset Management's MRK Position: Q2 2026 in Review

Baker Ellis Asset Management held its Merck (MRK) position steady in Q2 2026 at 14,988 shares worth $1.93M. The position accounts for 0.2% of the portfolio, ranked #88.

Baker Ellis Asset Management first reported a position in MRK in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.97M in Q1 2014. 1,867 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Baker Ellis Asset Management held 14,988 shares of Merck worth $1.93M as of Q2 2026.
  • Baker Ellis Asset Management left its Merck share count unchanged in Q2 2026.
  • Merck made up 0.2% of Baker Ellis Asset Management's portfolio in Q2 2026, its #88 holding.
  • Baker Ellis Asset Management first reported a position in Merck in Q2 2013 and has held it in 53 quarters since.
  • Baker Ellis Asset Management's Merck position peaked at $1.97M in Q1 2014.
  • 1,867 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Baker Ellis Asset Management's 13F filing for Q2 2026, filed 23 Jul 2026.